“randomised, double-blind, placebo-controlled study to determine the efficacy, safety, and pharmacokinetic profile of ATL1102 (25 mg and 50 mg) administered once weekly by subcutaneous injection for 52 weeks in non-ambulatory participants with DMD, to be conducted as a potentially pivotal (approvable) trial with a follow-on open label extension trial. Participants will be randomised to either 25 mg ATL1102,”
Don’t worry people .. games being played ”potentially pivotal (approvable) trial”
That means 1 trial away from commercialisation..$$$
ANP Price at posting:
24.5¢ Sentiment: Buy Disclosure: Held
